You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 康哲药业三连升累涨逾11% 地西泮鼻腔喷雾剂获美国FDA上市批准
格隆汇 01-14 11:27
格隆汇1月14日丨康哲药业(0867.HK)今日续涨,暂三连升累涨逾11%,现报11.18港元,涨5.47%,暂成交5654万港元,最新总市值277亿港元。康哲药业昨晚发公告称,美国FDA已批准其产品VALTOCO(地西泮鼻腔喷雾剂)作为一种急性治疗药物,用于治疗六岁及以上癫痫患者的间歇性、刻板性癫痫频繁发作活动。另外,集团已于近期获得了中国药监局对地西泮鼻喷雾剂的临床试验通知书。此外据悉,康哲药业曾在12月初发公告称拟携手剑桥大学等,对英国生物技术和生命科学领域进行投资。公司的投资将给公司在未来提供获得被投资公司所研发产品在大中华地区权利的机会。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account